On Monday, Fluor Corporation (NEW) (NYSE:FLR)’s shares declined -1.34% to $58.34, after Fluor Corporation (NEW)(FLR), declared that it signed a planned relationship contract with Goldcorp to serve as the Canadian mining corporation’s partner-of-choice for studies and engineering and construction services.
“We are honored to offer Goldcorp Fluor’s integrated services approach to support their mining projects,” said Rick Koumouris, president of Fluor’s Mining & Metals business. “By building a long-term relationship, we can deliver capital efficiency and enhance quality assurance on mining projects to assist Goldcorp deliver on its vision of ‘Together, Creating Sustainable Value.’”
In selecting Fluor, Goldcorp emphasized Fluor’s strong performance in the areas of safety, ethical business practices, stakeholder engagement, communications and innovation.
Fluor Corporation, through its auxiliaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project administration services worldwide. The corporation operates in five segments: Oil & Gas, Industrial & Infrastructure, Government, Global Services, and Power. The Oil & Gas segment offers a range of design, engineering, procurement, construction, and project administration services to upstream oil and gas production, liquefied natural gas, downstream refining, offshore production, pipeline, chemicals, and petrochemicals industries.
Accuray Incorporated (NASDAQ:ARAY)’s shares dropped -1.32% to $6.96, during the last trading session on Monday, hitting its highest level, as Accuray Incorporated (ARAY), will report results for its third quarter ended March 31, 2015 on April 30, 2015 after the market close. Administration will host a conference call to review the results at 1:30 p.m. PT/4:30 p.m. ET on the same day.
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The corporation offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, in addition to enables delivery of precise, high dose radiation while patients breathe normally.
At the end of Monday’s trade, AbbVie Inc (NYSE:ABBV)‘s shares dipped -0.47% to $61.20, after AbbVie Inc (ABBV), declared that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation during The International Liver CongressTM (ILC) 2015 in Vienna, Austria from April 22-26. Data being presented comprise sub-analyses of the recently approved VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets), Phase 3b studies, counting a head-to-head comparison of AbbVie’s three direct-acting antiviral treatment with telaprevir-based therapy and Phase 2/3 studies investigating AbbVie’s combination treatment in genotype 1 (GT1) and genotype 4 (GT4). Additionally, data from Phase 1 studies of ABT-493 and ABT-530 will be presented.
“We are happy to present new investigational data at ILC that reinforces our broad HCV clinical development program beyond the approval of VIEKIRAX + EXVIERA,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “We are studying the diverse populations seen in clinical practice and expanding our research and development, counting our new HCV pipeline compounds.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The corporation’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Coach, Inc. (NYSE:COH), ended its Monday’s trading session with -1.25% loss, and closed at $42.49, after Coach, Inc. (COH), declared that they have reached an 11-year exclusive worldwide fragrance license contract. Under the contract, Interparfums will create, produce and distribute new perfumes and fragrance-related products, counting new men’s and women’s scents. Interparfums will distribute these fragrances globally to department and specialty stores and duty free shops, in addition to in Coach retail stores starting fall 2016.
Victor Luis, Chief Executive Officer of Coach, Inc., said, “We’ve been happy with the performance of our fragrance business since our launch. As our brand transformation continues to progress, and with Interparfums as our partner, we know we can leverage this category into a much larger global opportunity. Given Interparfums’s successful track record of cultivating and growing fragrance lines for fashion and luxury goods brands they were the ideal choice to take our business to the next level.”
Coach, Inc. provides luxury accessories and lifestyle collections for women and men in the United States and internationally. It offers handbags, money pieces, wristlets, rings, charms, and cosmetic cases for women; and business cases, computer bags, messenger-style bags, totes, wallets, card cases, and belts, in addition to time administration and electronic accessories for men.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
